Xonef, eye drops 0.5% 5 ml

Csonef is a cardioselective beta1-adrenoblocker without intrinsic sympathomimetic activity. It has weak membrane stabilizing activity. It has hypotensive effect associated with reduction of cardiac output and decrease of sympathetic stimulation of peripheral vessels.

When used in therapeutic doses it does not have cardiodepressant effect, does not affect glucose metabolism, does not decrease the bronchodilator effect of beta-adrenomimetics and does not cause delay of sodium ions in the body. It works for a long time.

When used topically in the form of eye drops it reduces the increased intraocular pressure. The resorptive effect is expressed slightly.

Indications

Active ingredient

Composition

1 ml of eye drops contains:

the active ingredient:

betaxolol 5 mg (in the form of betaxolol hydrochloride),

excipients:

benzalkonium chloride;

hypromellose;

sodium chloride;

sodium hydroxide;

dinatrium edetate;

water for injection

How to take, the dosage

Push 1 drop 2 times a day into the affected eye.

In the first month therapy is carried out under control of intraocular pressure level, afterwards the frequency of intraocular pressure measurement is determined individually.

If betaxololol is used after previous treatment with another similar drug, the dosing regimen is determined individually.

Interaction

The concomitant use of Xonef and oral beta-adrenoblockers may increase the risk of adverse effects (both local and systemic) due to additive effects (therefore, patients receiving this drug combination should be under medical supervision).

When Xonef is used in combination with catecholamine depleting drugs (such as reserpine), decreased BP and bradycardia may be observed.

When concomitant administration of muscle relaxants and hypoglycemic agents, an increase in their effects may be observed.

In concomitant use with sympathomimetics, an increase in their vasoconstrictor effect.

Cautious use of Xonef and psychotropic drugs should be observed due to possible potentiation of their action.

Special Instructions

The drug is indicated with caution in patients:

Please note that beta-adrenoblockers may produce myasthenia-like symptoms (diplopia, ptosis, general weakness).

Beta-adrenoblockers should be gradually withdrawn 48 hours prior to general anesthesia before elective surgery because they may decrease myocardial sensitivity to sympathetic stimulation during general anesthesia.

Patients in whom beta-adrenoblockers are used may have a history of atopy or anaphylactic reactions. If repeated hypersensitivity reactions develop, these patients may not be sensitive to the usual doses of epinephrine (adrenaline) needed to stop anaphylaxis.

Beta-adrenoblockers may be absorbed into the systemic bloodstream when injected into the eye. In this case, the same side effects as in systemic use may be noted. Serious respiratory and cardiovascular disorders have been described, including fatal bronchospasm in patients with bronchial asthma and death from heart failure.

Csonef has minimal effect on BP and HR. However, caution should be exercised when prescribing the drug in patients with AV blockade of degree I and mild to moderate heart failure. Xonef therapy should be discontinued as soon as the first symptoms of decompensation on the cardiovascular system appear.

Xonef contains the preservative benzalkonium chloride which may precipitate on soft contact lenses and have a toxic effect on eye tissue. Therefore, patients who wear contact lenses should remove them before using the drops and put them back on no earlier than 20 minutes after injection.

If after use of the drops patients’ vision is temporarily reduced, it is not recommended to drive vehicles and engage in activities requiring increased attention and reaction until it is restored.

Contraindications

The drug should be used with caution in thyrotoxicosis, myasthenia, diabetes, Raynaud’s syndrome, pheochromocytoma, bronchial asthma, chronic obstructive bronchitis.

Side effects

Visually: often – short-term discomfort in the eye after injection, lacrimation; in some cases – decreased corneal sensitivity, red eyes, pinpoint keratitis, photophobia, photophobia, itching, feeling of “dry” eyes, allergic reactions.

Systemic side effects are rare:

Central nervous system: dizziness, nausea, somnolence, insomnia, headache, depression, increased symptoms of myasthenia gravis.

Cardiovascular system: bradycardia, impaired cardiac conduction and heart failure.

Respiratory system: dyspnea, bronchospasm, bronchial asthma, respiratory failure.

Overdose

In case of contact with the eyes with an excessive amount of the drug, the eyes should be rinsed with warm water.

Symptoms: in case of overdose of beta1-adrenoblockers there may be decrease in BP, bradycardia, acute heart failure.

Treatment: symptomatic therapy is carried out.

Pregnancy use

There is no sufficient experience of using Xonef in pregnancy and lactation.

The use of the drug during pregnancy and lactation (breastfeeding) is possible only when the expected benefits to the mother exceed the potential risk to the fetus or child.

Pediatric use

It is contraindicated in children and adolescents under 18 years of age.

Similarities